190 related articles for article (PubMed ID: 27692396)
1. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
7. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis.
Yalçinkaya Y; Artim Esen B; Amikishiyev S; Aliyeva N; Gül A; Öcal L; Inanç M
Turk J Med Sci; 2023; 53(6):1704-1712. PubMed ID: 38813512
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
11. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for rapidly progressive juvenile systemic sclerosis.
Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
[TBL] [Abstract][Full Text] [Related]
14. Targeting very early systemic sclerosis: a case-based review.
Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
16. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
17. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
[TBL] [Abstract][Full Text] [Related]
18. Role of rituximab in the treatment of systemic sclerosis: A literature review.
Yoshifuji H; Yomono K; Yamano Y; Kondoh Y; Yasuoka H
Mod Rheumatol; 2023 Nov; 33(6):1068-1077. PubMed ID: 37053127
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
